NF-κb expression, clinical course and inflammatory response after BAY-11-7082 prevented and treated
NF-κb level of spinal cord was detected in NF-κb blocker prevention and treatment group and EAE control group by western blot. As the Figure 4a shows, phosphorylated NF-κb level were lower in the EAE prevented and treated group than in the EAE control group(EAE vs. prevent: P<0.05).
We conducted experiments according to the grouping and administration methods introduced in the previous method. As shown in Figure 4b, the prevention group had a later disease onset than the EAE control group(P<0.001), with a lower symptom incidence(P<0.0001) and a lower score at the peak hour(P<0.0001). The treatment group had concurrent onset with EAE group; however, the score at peak hour was lower than EAE group(P<0.001).
After treated by the NF-κb blocker, the spinal inflammatory cell infiltrations were more severe in the EAE control groups than in the prevention and treatment groups(P<0.0001). LFB staining showed that spinal demyelination in the prevention and treatment groups was significantly less severe than that in the EAE control group(P<0.0001)(Figure 4c).
The pro-inflammatory cytokines, TNF-a, IL-6, IL-12p70 andIL-17A, were lower in the NF-κb blocker (prevent and treated) group than in the control group(P<0.05). Anti-inflammatory cytokines, IL-4 and IL-10 are higher in NF-κb prevent group(P<0.001), but no differences in treatment group(Figure 5a).